Clinical Trials Browser

Recruiting × Rectal Neoplasms × regorafenib × Clear all

NCT06911684 2026-04-28

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms